Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 16/20 | 0.43 |
| ▸ | GALR2 | O43603 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4358342 | 0.86 | ABL1 (0.56) | SCN9AABL1GALR2KDM4EGAA | |
| SCHEMBL3997867 | 0.86 | L3MBTL1 (0.50) | ABL1GALR2KDM4EMEN1KMT2A | |
| SCHEMBL13632603 | 0.86 | ALOX5 (0.46) | SCN9AKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL4002168 | 0.83 | ALOX5 (0.50) | ABL1BCRALOX5 | |
| SCHEMBL4138095 | 0.83 | GALR2 (0.45) | ABL1GALR2BCR | |
| SCHEMBL3450867 | 0.80 | GALR2 (0.51) | ABL1GALR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL3451194 | 0.76 | HPGD (0.52) | ABL1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL4132988 | 0.75 | KDM4E (0.54) | SCN9AKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL3451806 | 0.74 | GALR2 (0.53) | ABL1GALR2KDM4EMAPTBCR | |
| SCHEMBL4358482 | 0.74 | ABL1 (0.58) | ABL1GALR2KDM4EMAPTBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805142-A4 | NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS INC (US) | 2009-06-10 | — | — | EP | claimed |
| EP-1805142-A2 | NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | claimed |
| WO-2006034474-A2 | NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1805142-A4 | NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS INC (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1805142-A2 | NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | disclosed |
| WO-2006034474-A2 | NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | LDLR, LRP6, PLPBP | SCN9A 4622/4885ABL1 3158/4885GALR2 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.